Ventripoint Diagnostics Ltd. (TSXV: VPT; OTC: VPTDF) has released a corporate update outlining recent commercialisation milestones for its VMS+™ cardiac diagnostic system, including a completed sale to a U.S. midwest children's hospital and a system shipment to France for clinical evaluation. The company also announced a shareholder videoconference scheduled for Friday, October 9, 2026 at 1:00 p.m. EST. The update covers advances in partnerships, regulatory activities, board appointments, and capital markets engagement, offering investors a broad view of the company's current strategic priorities.

Key Points

  • Ventripoint Diagnostics Ltd. (TSXV: VPT; OTC: VPTDF) — AI-powered cardiac diagnostics company
  • Completed sale of one VMS+™ system to a U.S. midwest children's hospital and shipped a system to France for clinical evaluation
  • Shareholder videoconference set for October 9, 2026 at 1:00 p.m. EST via Zoom
  • Investors may be watching for commercialisation updates and financing progress discussed during the upcoming call

VMS+™ Commercialisation Progress in the U.S. and Europe

Ventripoint confirmed it closed the sale of one VMS+™ system to a U.S. midwest children's hospital and shipped a separate system to France for clinical evaluation. The release also states that increased use of a customer relationship management tool is generating new qualified leads, and that the company is engaging prospective customers through virtual demonstrations. These developments indicate continued effort to build a commercial pipeline for the AI-powered echocardiography platform, which holds regulatory approvals in the U.S., Europe, and Canada.

Partnership Expansion and Strategic Market Development

The company disclosed that its relationship with the Ollie Hinkle Heart Foundation has expanded to include additional congenital heart disease foundations — Jovie's Joy and Ella's Umbrella — to support U.S. system placements. Ventripoint also reported continued collaboration with Lishman Global on manufacturing and regulatory preparation for China market entry, and ongoing evaluation of distribution opportunities across Asia, South America, and the MENA region. Additionally, the company noted early-stage efforts to expand VMS+™ into valvular and structural heart applications, and acceptance into UBC's Health Innovation Intelligence program.

Board Appointment, Capital Markets Engagement, and Financing Activity

Ventripoint announced the recruitment of Dr. Philip Toleikis to its board of directors. On the capital markets front, the company disclosed engagements with Red Cloud for market maker services, More Capital for Canadian and U.S. business development, and Growthbridge Ventures for strategic advisory services related to institutional capital. The release also referenced a collaboration with Providence Innovation and PHV to pursue non-dilutive funding for system placement at the new St. Paul's Hospital. The immediate share price impact was not clear from available public information.

Shareholder Videoconference Scheduled for October 9

Ventripoint will host a shareholder videoconference on Friday, October 9, 2026 at 1:00 p.m. EST via Zoom, where management intends to provide additional context on recent developments, commercialisation priorities, and upcoming milestones. The meeting ID is 824 4505 4768 with passcode 557461, and dial-in options are available across multiple Canadian and U.S. cities. The release states the company appreciates continued shareholder support and looks forward to providing further updates during the call.